A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Basmisanil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Roche
- 27 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Jul 2019 Planned End Date changed from 30 Jan 2020 to 14 Dec 2019.
- 05 Jul 2019 Planned primary completion date changed from 26 Dec 2019 to 14 Dec 2019.